Abstract
This paper describes the formulation of a biodegradable microparticulate drug delivery system containing clodronate, a bisphosphonate intended for the treatment of bone diseases. Microspheres were prepared with several poly(D,L-lactide-co-glycolide) (PLGA) copolymers of various molecular weights and molar compositions and 1 poly(D,L-lactide) (PDLLA) homopolymer by a water-in-oil-in-water (w/o/w) double emulsion solvent evaporation procedure. Critical process parameters and formulation variables (ie, addition of stabilizing agents) were evaluated for their effect on drug encapsulation efficiency and clodronate release rate from microparticles Well-formed clodronate-loaded microspheres were obtained for all polymers by selecting suitable process parameters (inner water/oil volume ratio 1∶16, temperature-raising rate in the solvent evaporation step 1°C/min, 2% wt/vol NaCl in the external aqueous phase). Good yields were obtained in all batches of clodronate microspheres (above 60%); drug encapsulation efficiencies ranged between 49% and 75% depending on the polymer used. Clodronate release from all copolymer microspheres was completed in about 48 hours, while those from PDLLA microspheres required about 20 days. The change of microsphere composition by adding a surfactant such as Span 20 or a viscosing agent such as carboxymethylcellulose extended the long-term release up to 3 months. Clodronate was successfully entrapped in PLGA and PDLLA microspheres, and drug release could be modulated from 48 hours up to 3 months by suitable selection of polymer, composition, additives, and manufacturing conditions.
KeyWords: PLGA microspheres, solvent evaporation method, long-term release, Clodronate
Full Text
The Full Text of this article is available as a PDF (1.3 MB).
References
- 1.Delmas PD, Meunier PJ. The management of Paget's disease of bone. New Engl J Med. 1997;336:558–566. doi: 10.1056/NEJM199702203360807. [DOI] [PubMed] [Google Scholar]
- 2.Kanis JA. Rationale for the use of bisphosphonates in breast cancer. Acta Oncol. 1996;35(Suppl 5):61–67. doi: 10.3109/02841869609083972. [DOI] [PubMed] [Google Scholar]
- 3.Fleisch H. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997;29:55–62. doi: 10.3109/07853899708998743. [DOI] [PubMed] [Google Scholar]
- 4.Shinoda H, Adamek G, Felix R, Fleish H, Schenk R. Structure-activity relationship of various bisphosphonates. Cale Tissue Int. 1983;35:87–99. doi: 10.1007/BF02405012. [DOI] [PubMed] [Google Scholar]
- 5.Yakatan GJ, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther. 1982;31:402–410. doi: 10.1038/clpt.1982.51. [DOI] [PubMed] [Google Scholar]
- 6.Lauren L, Osterman T, Karhi T. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol Toxicol. 1991;69:365–368. doi: 10.1111/j.1600-0773.1991.tb01312.x. [DOI] [PubMed] [Google Scholar]
- 7.Rossini M, Gatti D, Gerardi D, Zamberlan N, Braga V, Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 1999;24:125–129. doi: 10.1016/S8756-3282(98)00154-9. [DOI] [PubMed] [Google Scholar]
- 8.Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Del Rev. 2000;42:175–195. doi: 10.1016/S0169-409X(00)00061-2. [DOI] [PubMed] [Google Scholar]
- 9.Patashnik S, Rabinovich L, Golomb G. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J Drug Targ. 1997;4:371–380. doi: 10.3109/10611869709017894. [DOI] [PubMed] [Google Scholar]
- 10.Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12:1–99. doi: 10.1615/critrevtherdrugcarriersyst.v12.i1.10. [DOI] [PubMed] [Google Scholar]
- 11.Gogolewski S, Mainil-Varlet P. Effect of thermal treatment on sterility, molecular and mechanical properties of various polylactides. Biomaterials. 1997;18:251–255. doi: 10.1016/S0142-9612(96)00132-9. [DOI] [PubMed] [Google Scholar]
- 12.Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic glycolic acid) microspheres. Pharm Res. 1991;8:713–720. doi: 10.1023/A:1015841715384. [DOI] [PubMed] [Google Scholar]
- 13.Ostovic D, Stelmach C, Hulshizer B. Formation of a chromophoric complex between alendronate and copper (II) ions. Pharm Res. 1993;10:470–472. doi: 10.1023/A:1018969112754. [DOI] [PubMed] [Google Scholar]
- 14.Uchida T, Yoshida K, Goto S. Preparation and characterization of polylactic acid microspheres containing water-soluble dyes using a novel w/o/w emulsion solvent evaporation method. J Microencapsul. 1996;13:219–228. doi: 10.3109/02652049609052909. [DOI] [PubMed] [Google Scholar]
- 15.Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic glycolic) acid. Chem Pharm Bull. 1988;36:1095–1103. doi: 10.1248/cpb.36.1095. [DOI] [PubMed] [Google Scholar]
- 16.Baker RW. Biodegradable systems. In: Baker R, editor. Controlled release of biologically active agents. New York: John Wiley & Sons; 1987. pp. 84–131. [Google Scholar]